基于PLCO癌症筛查试验扩展随访的阿司匹林使用与卵巢癌风险
基于PLCO癌症筛查试验1993至2001年入组、随访至2014年的41633名绝经后女性,其中223例发生卵巢癌,采用Cox回归分析阿司匹林使用与卵巢癌风险关联;总体无显著关联(HR 0.93,95%CI 0.72-1.21),<70岁女性每日低剂量阿司匹林使用呈提示性负关联(HR 0.64,95%CI 0.38-1.09),但事件数少、估计不精确,需进一步研究确认。
要点
- 总体阿司匹林使用与卵巢癌风险无显著关联(HR 0.93,95%CI 0.72-1.21)。
- <70岁女性每日使用低剂量阿司匹林呈提示性负关联(HR 0.64,95%CI 0.38-1.09)。
- 事件数少致效应估计不精确,需进一步研究确认并扩展这些发现。
核心结论
- 这些发现提示每日低剂量阿司匹林可能对降低卵巢癌风险有潜在适度效应,但事件数少致效应估计不精确,需进一步研究确认并扩展这些发现。
研究设计与样本
- 前列腺、肺、结直肠和卵巢(PLCO)癌症筛查试验中的绝经后女性,1993至2001年入组,随访至2014年。
- 阿司匹林使用详细数据(如剂量、频率和持续时间)通过2006-2007年实施的补充问卷(SQX)获取。
- 采用Cox比例风险回归计算阿司匹林使用(定义为≥每周一次)与 incident 卵巢癌关联的风险比(HR)和95%置信区间(CI)。
- 分析在全部研究样本女性中进行,并按SQX时年龄分层。
- 共纳入41633名女性,其中223例发生 incident 卵巢癌。
主要发现
- 总体阿司匹林使用与卵巢癌风险无显著关联(HR:0.93,95%CI:0.72-1.21)。
- 在<70岁女性中,每日使用阿司匹林呈提示性负关联(HR:0.65,95%CI:0.40-1.05)。
- 在<70岁女性中,低剂量阿司匹林使用呈提示性负关联(HR:0.79,95%CI:0.51-1.24)。
- 在<70岁女性中,每日使用低剂量阿司匹林呈提示性负关联(HR:0.64,95%CI:0.38-1.09)。
局限性
- 事件数少致效应估计不精确。
- 需进一步研究确认并扩展这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Frequent use of aspirin has been associated with reduced ovarian cancer risk in observational studies, but it is unclear if only daily, low-dose aspirin confers a protective benefit. We examined associations between patterns of aspirin use and ovarian cancer risk among postmenopausal women in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. METHODS: Participants were enrolled in PLCO between 1993 and 2001 and followed for cancer outcomes through 2014. Detailed data on aspirin use (e.g., dose, frequency and duration) were ascertained via the supplemental questionnaire (SQX) administered in 2006-2007. We used Cox proportional hazards regression to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between aspirin use (defined as use ≥once/week) and incident ovarian cancer. We conducted analyses among all women in the study sample and stratified by age at the time of the SQX. RESULTS: There were 41,633 women included in this analysis, of whom 223 developed incident ovarian cancer. Overall, aspirin use was not significantly associated with ovarian cancer risk (HR: 0.93, 95% CI: 0.72-1.21). Among women <70 years, there was suggestion of an inverse association for daily use of aspirin (HR: 0.65, 95% CI: 0.40-1.05), low-dose aspirin (HR: 0.79, 95% CI: 0.51-1.24) and daily use of low-dose aspirin (HR: 0.64, 95% CI: 0.38-1.09). CONCLUSIONS: These findings suggest a potential modest effect of daily, low-dose aspirin in reducing ovarian cancer risk. However, effect estimates were imprecise given the small number of events, and further research will be needed to confirm and extend these findings.
引用
- Hurwitz LM, Pinsky PF, Huang WY, et al. Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial. Gynecol Oncol. 2020. PMID: 32919779. doi:10.1016/j.ygyno.2020.08.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。